BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31:2963-2969. [PMID: 23835712 DOI: 10.1200/jco.2013.49.5283] [Cited by in Crossref: 229] [Cited by in F6Publishing: 91] [Article Influence: 25.4] [Reference Citation Analysis]
Number Citing Articles
1 Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A 2018;115:2467-72. [PMID: 29453278 DOI: 10.1073/pnas.1719264115] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 16.0] [Reference Citation Analysis]
2 Laakmann E, Witzel I, Fasching PA, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Zahm DM, Blohmer JU, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res 2019;21:60. [PMID: 31077239 DOI: 10.1186/s13058-019-1144-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
3 Abdul Sultan A, Mallen C, Hayward R, Muller S, Whittle R, Hotston M, Roddy E. Gout and subsequent erectile dysfunction: a population-based cohort study from England. Arthritis Res Ther 2017;19:123. [PMID: 28587655 DOI: 10.1186/s13075-017-1322-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
4 Rosenberg AS, Brunson A, Jonas BA, Keegan THM, Wun T. Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. J Natl Cancer Inst 2019;111:78-85. [PMID: 29897481 DOI: 10.1093/jnci/djy073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
5 Kaura A, Sterne JAC, Trickey A, Abbott S, Mulla A, Glampson B, Panoulas V, Davies J, Woods K, Omigie J, Shah AD, Channon KM, Weber JN, Thursz MR, Elliott P, Hemingway H, Williams B, Asselbergs FW, O'Sullivan M, Lord GM, Melikian N, Johnson T, Francis DP, Shah AM, Perera D, Kharbanda R, Patel RS, Mayet J. Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. Lancet 2020;396:623-34. [PMID: 32861307 DOI: 10.1016/S0140-6736(20)30930-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
6 Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Choti MA, Minter RR, Wang SC, Porembka MR. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis. JAMA Oncol 2018;4:31-8. [PMID: 28975352 DOI: 10.1001/jamaoncol.2017.2805] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
7 Chiu WC, Shan JC, Yang YH, Chen VC, Chen PC. Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder. Drug Alcohol Depend 2021;228:109096. [PMID: 34600254 DOI: 10.1016/j.drugalcdep.2021.109096] [Reference Citation Analysis]
8 Pollom EL, Alagappan M, Park LS, Whittemore AS, Koong AC, Chang DT. Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med. 2017;6:129-141. [PMID: 27891822 DOI: 10.1002/cam4.975] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
9 Mehtsun WT, McCleary NJ, Maduekwe UN, Wolpin BM, Schrag D, Wang J. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. JAMA Oncol 2021. [PMID: 34854874 DOI: 10.1001/jamaoncol.2021.5407] [Reference Citation Analysis]
10 Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, deGregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C. Response to Di Cosimo, Torri, and Porcu. J Natl Cancer Inst 2019;111:1234-5. [PMID: 31187135 DOI: 10.1093/jnci/djz095] [Reference Citation Analysis]
11 Buttigliero C, Tucci M, Vignani F, Di Maio M. Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias? J Clin Oncol 2017;35:1264. [PMID: 28165894 DOI: 10.1200/JCO.2016.69.3580] [Reference Citation Analysis]
12 Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M; SORAMIC study group. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging 2022;22:1. [PMID: 34983668 DOI: 10.1186/s40644-021-00439-x] [Reference Citation Analysis]
13 Mandala M, Larkin J, Ascierto PA, Del Vecchio M, Gogas H, Cowey CL, Arance A, Dalle S, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez I, Butler MO, Di Giacomo AM, Lutzky J, De La Cruz-Merino L, Atkinson V, Arenberger P, Hill A, Fecher L, Millward M, Khushalani NI, de Pril V, Lobo M, Weber J. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. J Immunother Cancer 2021;9:e003188. [PMID: 34452930 DOI: 10.1136/jitc-2021-003188] [Reference Citation Analysis]
14 Agarwal P, Moshier E, Ru M, Ohri N, Ennis R, Rosenzweig K, Mazumdar M. Immortal Time Bias in Observational Studies of Time-to-Event Outcomes: Assessing Effects of Postmastectomy Radiation Therapy Using the National Cancer Database. Cancer Control 2018;25:1073274818789355. [PMID: 30021466 DOI: 10.1177/1073274818789355] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
15 Sultan AA, Whittle R, Muller S, Roddy E, Mallen CD, Bucknall M, Helliwell T, Hider S, Paskins Z. Risk of fragility fracture among patients with gout and the effect of urate-lowering therapy. CMAJ 2018;190:E581-7. [PMID: 29759964 DOI: 10.1503/cmaj.170806] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol 2019;37:471-80. [PMID: 30615550 DOI: 10.1200/JCO.18.00690] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 11.7] [Reference Citation Analysis]
17 Lee J, Yu T, Tsai MH. Lymph Node Number Predicts the Efficacy of Adjuvant Chemoradiotherapy in Node-Positive Endometrial Cancer Patients. Diagnostics (Basel) 2020;10:E373. [PMID: 32512893 DOI: 10.3390/diagnostics10060373] [Reference Citation Analysis]
18 Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y. Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer 2019;8:505-19. [PMID: 31799207 DOI: 10.1159/000503032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Weberpals J, Jansen L, Silversmit G, Verbeeck J, van der Geest L, Vissers PA, Zadnik V, Brenner H. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients. Clin Epidemiol 2018;10:1109-25. [PMID: 30214315 DOI: 10.2147/CLEP.S160973] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
20 Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology 2016;5:e1191732. [PMID: 27622047 DOI: 10.1080/2162402X.2016.1191732] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
21 Huang YC, Shen SM, Liu CY, Pavlidis S, Wang CL, Ko HW, Chung FT, Lin TY, Feng PH, Lee KY, Guo YK, Yang CT, Kuo CS. Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer. Thorac Cancer 2018;9:1648-55. [PMID: 30259696 DOI: 10.1111/1759-7714.12875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Schmidt SA, Lash TL. Immortal person-time bias in the association between herpes zoster and survival following autologous stem cell transplantation. Bone Marrow Transplant 2015;50:878-9. [PMID: 25822225 DOI: 10.1038/bmt.2015.66] [Reference Citation Analysis]
23 Swords DS, Scaife CL. Decompositions of the Contribution of Treatment Disparities to Survival Disparities in Stage I-II Pancreatic Adenocarcinoma. Ann Surg Oncol 2021;28:3157-68. [PMID: 33145705 DOI: 10.1245/s10434-020-09267-y] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Boudewijns S, Westdorp H, Koornstra RH, Aarntzen EH, Schreibelt G, Creemers JH, Punt CJ, Figdor CG, de Vries IJ, Gerritsen WR, Bol KF. Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. J Immunother 2016;39:241-8. [PMID: 27227325 DOI: 10.1097/CJI.0000000000000127] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
25 Ochi H, Hiraoka A, Hirooka M, Koizumi Y, Amano M, Azemoto N, Watanabe T, Yoshida O, Tokumoto Y, Mashiba T, Yokota T, Abe M, Michitaka K, Hiasa Y, Joko K. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol 2021;56:90-100. [PMID: 33278003 DOI: 10.1007/s00535-020-01747-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lim HH, Hopkins AM, Rowland A, Yuen HY, Karapetis CS, Sorich MJ. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. Target Oncol 2019;14:743-8. [PMID: 31676953 DOI: 10.1007/s11523-019-00683-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun 2021;12:5563. [PMID: 34548479 DOI: 10.1038/s41467-021-25769-z] [Reference Citation Analysis]
28 Haug EB, Markovitz AR, Fraser A, Dalen H, Romundstad PR, Åsvold BO, Rich-Edwards JW, Horn J. The role of cardiovascular risk factors in maternal cardiovascular disease according to offspring birth characteristics in the HUNT study. Sci Rep 2021;11:22981. [PMID: 34837029 DOI: 10.1038/s41598-021-99478-4] [Reference Citation Analysis]
29 Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.Front Oncol. 2020;10:41. [PMID: 32083002 DOI: 10.3389/fonc.2020.00041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
30 Xia LY, Xu WY, Hu QL. The different outcomes between breast-conserving surgery plus radiotherapy and mastectomy in metaplastic breast cancer: A population-based study. PLoS One 2021;16:e0256893. [PMID: 34473783 DOI: 10.1371/journal.pone.0256893] [Reference Citation Analysis]
31 Simon M, Bosset PO, Rouanne M, Benhamou S, Radulescu C, Molinié V, Neuzillet Y, Paoletti X, Lebret T. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. PLoS One 2019;14:e0211721. [PMID: 30811419 DOI: 10.1371/journal.pone.0211721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
32 Kamarajah SK, Bednar F, Cho CS, Nathan H. Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis. J Gastrointest Surg 2021;25:1805-14. [PMID: 33230687 DOI: 10.1007/s11605-020-04879-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Gordon AC, Gradishar WJ, Kaklamani VG, Thuluvath AJ, Ryu RK, Sato KT, Gates VL, Salem R, Lewandowski RJ. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014;25:1523-1532, 1532.e1-1532.e2. [PMID: 25156827 DOI: 10.1016/j.jvir.2014.07.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
34 Nassour I, Hynan LS, Christie A, Minter RM, Yopp AC, Choti MA, Mansour JC, Porembka MR, Wang SC. Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. J Gastrointest Surg 2018;22:695-702. [PMID: 29127604 DOI: 10.1007/s11605-017-3624-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
35 Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging 2014;14:30. [PMID: 25609545 DOI: 10.1186/s40644-014-0030-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
36 Saglio G, Fava C, Gale RP. Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia? Haematologica 2019;104:862-4. [PMID: 31040230 DOI: 10.3324/haematol.2018.214445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Faiena I, Salmasi A, Mendhiratta N, Lenis AT, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. World J Urol 2018;36:1825-33. [PMID: 29752514 DOI: 10.1007/s00345-018-2327-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Westdorp H, Creemers JHA, van Oort IM, Schreibelt G, Gorris MAJ, Mehra N, Simons M, de Goede AL, van Rossum MM, Croockewit AJ, Figdor CG, Witjes JA, Aarntzen EHJG, Mus RDM, Brüning M, Petry K, Gotthardt M, Barentsz JO, de Vries IJM, Gerritsen WR. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J Immunother Cancer 2019;7:302. [PMID: 31727154 DOI: 10.1186/s40425-019-0787-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
39 Gan CL, Dudani S, Wells JC, Donskov F, Pal SK, Dizman N, Rathi N, Beuselinck B, Yan F, Lalani AA, Hansen A, Szabados B, de Velasco G, Tran B, Lee JL, Vaishampayan UN, Bjarnason GA, Subasri M, Choueiri TK, Heng DYC. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Med 2021;10:1212-21. [PMID: 33463028 DOI: 10.1002/cam4.3717] [Reference Citation Analysis]
40 Kamarajah SK, White SA, Naffouje SA, Salti GI, Dahdaleh F. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study. Ann Surg Oncol 2021. [PMID: 33786676 DOI: 10.1245/s10434-021-09823-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, Saglio G, Gale RP. Chronic myeloid leukemia stem cells. Leukemia. 2019;. [PMID: 31127148 DOI: 10.1038/s41375-019-0490-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 17.7] [Reference Citation Analysis]
42 Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget 2016;7:13209-20. [PMID: 26334099 DOI: 10.18632/oncotarget.4801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H; Cancer Genome Atlas Research Network. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 2018;173:400-416.e11. [PMID: 29625055 DOI: 10.1016/j.cell.2018.02.052] [Cited by in Crossref: 760] [Cited by in F6Publishing: 708] [Article Influence: 253.3] [Reference Citation Analysis]
44 Di Girolamo C, Walters S, Gildea C, Benitez Majano S, Rachet B, Morris M. Can we assess Cancer Waiting Time targets with cancer survival? A population-based study of individually linked data from the National Cancer Waiting Times monitoring dataset in England, 2009-2013. PLoS One 2018;13:e0201288. [PMID: 30133466 DOI: 10.1371/journal.pone.0201288] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
45 Zumsteg ZS, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, Shiao SL, Mita AC, Scher KS, Sherman EJ, Lee NY, Ho AS. Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. Cancer 2017;123:4583-93. [PMID: 28817183 DOI: 10.1002/cncr.30933] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
46 Kucharczyk MJ, Parpia S, Whitton A, Greenspoon JN. Evaluation of pseudoprogression in patients with glioblastoma. Neurooncol Pract 2017;4:120-34. [PMID: 31386017 DOI: 10.1093/nop/npw021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
47 Ye W, Olsson-Brown A, Watson RA, Cheung VTF, Morgan RD, Nassiri I, Cooper R, Taylor CA, Akbani U, Brain O, Matin RN, Coupe N, Middleton MR, Coles M, Sacco JJ, Payne MJ, Fairfax BP. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. Br J Cancer 2021;124:1661-9. [PMID: 33723392 DOI: 10.1038/s41416-021-01310-3] [Reference Citation Analysis]
48 Garderet L, Laubach JP, Stoppa AM, Hari P, Cavo M, Ludwig H, Mateos MV, Luptakova K, Lin J, Yung G, van de Velde H, Berg D, Moreau P, Richardson PG. Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia 2018;32:2032-6. [PMID: 29568098 DOI: 10.1038/s41375-018-0091-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
49 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
50 Yoo D, Kim N, Hwang DW, Song KB, Lee JH, Lee W, Kwon J, Park Y, Hong S, Lee JW, Hwang K, Shin D, Tak E, Kim SC. Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma. J Clin Med 2020;9:E1953. [PMID: 32580502 DOI: 10.3390/jcm9061953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Fukuokaya W, Kimura T, Yanagisawa T, Kimura S, Tsuzuki S, Koike Y, Iwamoto Y, Enei Y, Tanaka M, Urabe F, Onuma H, Honda M, Miki J, Oyama Y, Abe H, Egawa S. Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma. Cancer Immunol Immunother 2021. [PMID: 34100985 DOI: 10.1007/s00262-021-02980-x] [Reference Citation Analysis]
52 Warner A, Pickles T, Crook J, Martin AG, Souhami L, Catton C, Lukka H, Rodrigues G. Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer. Cureus 2015;7:e276. [PMID: 26180700 DOI: 10.7759/cureus.276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
53 Movsas B, Hu C, Sloan J, Bradley J, Komaki R, Masters G, Kavadi V, Narayan S, Michalski J, Johnson DW, Koprowski C, Curran WJ Jr, Garces YI, Gaur R, Wynn RB, Schallenkamp J, Gelblum DY, MacRae RM, Paulus R, Choy H. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol 2016;2:359-67. [PMID: 26606200 DOI: 10.1001/jamaoncol.2015.3969] [Cited by in Crossref: 92] [Cited by in F6Publishing: 86] [Article Influence: 15.3] [Reference Citation Analysis]
54 Ollila TA, Olszewski AJ. Radiation therapy in primary testicular lymphoma: does practice match the standard of care? Leuk Lymphoma 2019;60:523-6. [PMID: 29966467 DOI: 10.1080/10428194.2018.1480776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Arciero C, Liu Y, Gillespie T, Subhedar P. Surgery and survival in patients with stage IV breast cancer. Breast J 2019;25:644-53. [PMID: 31087448 DOI: 10.1111/tbj.13296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
56 Paoletti C, Regan MM, Niman SM, Dolce EM, Darga EP, Liu MC, Marcom PK, Hart LL, Smith JW 2nd, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Brown ME, McCormack RT, Hayes DF. Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. NPJ Breast Cancer 2021;7:77. [PMID: 34117261 DOI: 10.1038/s41523-021-00281-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 De Mattos-Arruda L, Shen R, Reis-Filho JS, Cortés J. Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol 2016;13:566-79. [PMID: 27000962 DOI: 10.1038/nrclinonc.2016.35] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
58 Cho IS, Chae YR, Kim JH, Yoo HR, Jang SY, Kim GR, Nam CM. Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study. BMC Med Res Methodol 2017;17:126. [PMID: 28830373 DOI: 10.1186/s12874-017-0405-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
59 Brauer DG, Fields RC, Tan BR Jr, Doyle MBM, Hammill CW, Hawkins WG, Colditz GA, Chapman WC. Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma. HPB (Oxford) 2018;20:470-6. [PMID: 29370972 DOI: 10.1016/j.hpb.2017.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol 2022;40:127-37. [PMID: 34818112 DOI: 10.1200/JCO.21.02229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Souchon R. [Safe pregnancy after breast cancer treatment in patients carrying BRCA mutations?]. Strahlenther Onkol 2021;197:159-61. [PMID: 33313957 DOI: 10.1007/s00066-020-01726-5] [Reference Citation Analysis]
62 Roughley M, Sultan AA, Clarson L, Muller S, Whittle R, Belcher J, Mallen CD, Roddy E. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. Arthritis Res Ther 2018;20:243. [PMID: 30376864 DOI: 10.1186/s13075-018-1746-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
63 Sanfilippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, Gumbel J, Blue B, O'Brian K, Carson KR. Statins Are Associated With Reduced Mortality in Multiple Myeloma. J Clin Oncol 2016;34:4008-14. [PMID: 27646948 DOI: 10.1200/JCO.2016.68.3482] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
64 Jairam V, Park HS. Strengths and limitations of large databases in lung cancer radiation oncology research. Transl Lung Cancer Res 2019;8:S172-83. [PMID: 31673522 DOI: 10.21037/tlcr.2019.05.06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
65 Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol 2018;4:1543-52. [PMID: 30193240 DOI: 10.1001/jamaoncol.2018.3676] [Cited by in Crossref: 303] [Cited by in F6Publishing: 313] [Article Influence: 101.0] [Reference Citation Analysis]
66 Osterlund P, Salminen T, Soveri LM, Kallio R, Kellokumpu I, Lamminmäki A, Halonen P, Ristamäki R, Lantto E, Uutela A, Osterlund E, Ovissi A, Nordin A, Heervä E, Lehtomäki K, Räsänen J, Murashev M, Aroviita L, Jekunen A, Lindvall-Andersson R, Nyandoto P, Kononen J, Lepistö A, Poussa T, Muhonen T, Ålgars A, Isoniemi H; Members of The RAXO study group are collaborators of this study and are listed in Appendix Table 4B. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur 2021;3:100049. [PMID: 34557799 DOI: 10.1016/j.lanepe.2021.100049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
67 Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultsides GA, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 2016;8:364ra155. [PMID: 27831904 DOI: 10.1126/scitranslmed.aai8545] [Cited by in Crossref: 187] [Cited by in F6Publishing: 187] [Article Influence: 37.4] [Reference Citation Analysis]
68 Rovers KP, Bakkers C, van Erning FN, Burger JWA, Nienhuijs SW, Simkens GAAM, Creemers GM, Hemmer PHJ, Punt CJA, Lemmens VEPP, Tanis PJ, de Hingh IHJT. Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. JAMA Oncol 2020;6:e202701. [PMID: 32672798 DOI: 10.1001/jamaoncol.2020.2701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
69 Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, Hodi FS, Wolchok JD, Mitchell TC, Hersey P, Dronca R, Joseph RW, Boutros C, Min L, Long GV, Schachter J, Puzanov I, Dummer R, Lin J, Ibrahim N, Diede SJ, Carlino MS, Joshua AM. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer 2021;144:182-91. [PMID: 33360855 DOI: 10.1016/j.ejca.2020.11.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
70 Chen L, Sun T, Wu L, Zhang W, Ren Y, Xiang D, Liang B, Zheng C. The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma. J Oncol 2021;2021:8169012. [PMID: 34840572 DOI: 10.1155/2021/8169012] [Reference Citation Analysis]
71 Hu YW. Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Eur Urol 2016;70:e158. [PMID: 27166669 DOI: 10.1016/j.eururo.2016.04.038] [Reference Citation Analysis]
72 Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart M, Gelber RD, de Azambuja E. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. J Natl Cancer Inst 2019;111:86-94. [PMID: 29878225 DOI: 10.1093/jnci/djy094] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 19.5] [Reference Citation Analysis]
73 Pfail JL, Audenet F, Martini A, Tomer N, Paranjpe I, Daza J, Attalla K, Waingankar N, Mehrazin R, Wiklund P, Galsky MD, Sfakianos JP. Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. BLC 2020;6:265-76. [DOI: 10.3233/blc-200303] [Reference Citation Analysis]
74 Wu CE, Yang CK, Peng MT, Huang PW, Chang CF, Yeh KY, Chen CB, Wang CL, Hsu CW, Chen IW, Lin CT, Ueng SH, Lin G, Lin YF, Cheng CY, Chang JW. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies. BMC Cancer 2020;20:1018. [PMID: 33087090 DOI: 10.1186/s12885-020-07508-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmström P, Werutsky G, Bogaerts J, Bergh J, Cameron DA; EORTC 10994/BIG 1-00 Study investigators. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol 2014;25:1128-36. [PMID: 24618153 DOI: 10.1093/annonc/mdu118] [Cited by in Crossref: 98] [Cited by in F6Publishing: 103] [Article Influence: 12.3] [Reference Citation Analysis]
76 Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol 2018;36:2845-53. [PMID: 30125215 DOI: 10.1200/JCO.2018.78.5246] [Cited by in Crossref: 127] [Cited by in F6Publishing: 76] [Article Influence: 31.8] [Reference Citation Analysis]
77 Buyse M, Burzykowski T, Saad ED. The search for surrogate endpoints for immunotherapy trials. Ann Transl Med 2018;6:231. [PMID: 30023394 DOI: 10.21037/atm.2018.05.16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
78 Winter J, Lenders MM, Gassenmaier M, Forschner A, Leiter U, Weide B, Purde MT, Flatz L, Cozzio A, Röcken M, Garbe C, Eigentler TK, Wagner NB. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:1089-99. [PMID: 33113003 DOI: 10.1007/s00262-020-02768-5] [Reference Citation Analysis]
79 Chang JS, Choi JE, Park MH, Jung SH, Choi BO, Park HS, Park S, Kim YB; Korean Breast Cancer Society. Trends in the Application of Postmastectomy Radiotherapy for Breast Cancer With 1 to 3 Positive Axillary Nodes and Tumors ≤5 cm in the Modern Treatment Era: A Retrospective Korean Breast Cancer Society Report. Medicine (Baltimore) 2016;95:e3592. [PMID: 27175662 DOI: 10.1097/MD.0000000000003592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
80 Hendlisz A, Deleporte A, Delaunoit T, Maréchal R, Peeters M, Holbrechts S, Van den Eynde M, Houbiers G, Filleul B, Van Laethem JL, Ceyssens S, Barbuto AM, Lhommel R, Demolin G, Garcia C, El Mansy H, Ameye L, Moreau M, Guiot T, Paesmans M, Piccart M, Flamen P. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. PLoS One 2015;10:e0138341. [PMID: 26421426 DOI: 10.1371/journal.pone.0138341] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
81 Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, Pietrantonio F, Santini D, Allegrini G, Daniel F, Pagani F, Antoniotti C, Zaniboni A, Conca V, Latiano TP, Boccaccino A, Passardi A, Tamburini E, Masi G, Di Maio M, Cremolini C. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. Cancer Treat Rev 2021;103:102326. [PMID: 35016085 DOI: 10.1016/j.ctrv.2021.102326] [Reference Citation Analysis]
82 Li L, Yang Z, Hou Y, Chen Z. Moving beyond the Cox proportional hazards model in survival data analysis: a cervical cancer study. BMJ Open 2020;10:e033965. [PMID: 32690495 DOI: 10.1136/bmjopen-2019-033965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Dionigi E, Garcovich M, Borzio M, Leandro G, Majumdar A, Tsami A, Arvaniti V, Roccarina D, Pinzani M, Burroughs AK, O'Beirne J, Tsochatzis EA. Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. Am J Gastroenterol. 2017;112:588-596. [PMID: 28220780 DOI: 10.1038/ajg.2017.19] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
84 Rengarajan M, Gainor JF. Endocrine immune-related adverse events: a double-edged sword? Transl Lung Cancer Res 2021;10:13-7. [PMID: 33569289 DOI: 10.21037/tlcr-2020-16] [Reference Citation Analysis]
85 Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol 2020;15:449-66. [PMID: 32725437 DOI: 10.1007/s11523-020-00738-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
86 Kwee SA, Wong LL, Sato MM, Acoba JD, Rho YS, Srivastava A, Landsittel DP. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation. J Vasc Interv Radiol 2021;32:1258-1266.e6. [PMID: 34242775 DOI: 10.1016/j.jvir.2021.07.001] [Reference Citation Analysis]
87 Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr. Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. J Natl Cancer Inst 2016;108:djw037. [PMID: 27098150 DOI: 10.1093/jnci/djw037] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
88 Suker M, Nuyttens JJ, Groot Koerkamp B, Eskens FALM, van Eijck CHJ. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. J Surg Oncol 2018;118:1021-6. [PMID: 30259526 DOI: 10.1002/jso.25233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
89 Lenis AT, Burton CS, Golla V, Pooli A, Faiena I, Johnson DC, Salmasi A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. Urol Oncol 2019;37:577.e9-577.e16. [PMID: 30930099 DOI: 10.1016/j.urolonc.2019.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
90 Behera M, Steuer CE, Liu Y, Fernandez F, Fu C, Higgins KA, Gillespie TW, Pakkala S, Pillai RN, Force S, Belani CP, Khuri FR, Curran WJ, Ramalingam SS. Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. Oncologist 2020;25:e964-75. [PMID: 31943520 DOI: 10.1634/theoncologist.2019-0661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
91 Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 2016;34:3400-8. [PMID: 27325862 DOI: 10.1200/JCO.2015.65.6595] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
92 Thompson LL, Chang MS, McCormack L, Polyakov N, Yoon J, Song H, Huang JT, Chen ST. Patterns of cutaneous immune-related adverse events in adults and children with advanced sarcoma: a retrospective cohort study. Br J Dermatol 2021;184:363-5. [PMID: 32894776 DOI: 10.1111/bjd.19540] [Reference Citation Analysis]
93 Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, Hamilton EG, Yang YD, Lovejoy A, Newman AM, Kurtz DM, Jin M, Schroers-Martin J, Stehr H, Liu CL, Hui AB, Patel V, Maru D, Lin SH, Alizadeh AA, Diehn M. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology 2020;158:494-505.e6. [PMID: 31711920 DOI: 10.1053/j.gastro.2019.10.039] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
94 Kamarajah SK, Al-Rawashdeh W, White SA, Abu Hilal M, Salti GI, Dahdaleh FS. Adjuvant radiotherapy improves long-term survival after resection for gallbladder cancer A population-based cohort study. Eur J Surg Oncol 2021:S0748-7983(21)00724-1. [PMID: 34518052 DOI: 10.1016/j.ejso.2021.09.002] [Reference Citation Analysis]
95 Hu H, Wang L, Li C, Ge W, Xia J. An improved method for the effect estimation of the intermediate event on the outcome based on the susceptible pre-identification. BMC Med Res Methodol 2021;21:192. [PMID: 34548029 DOI: 10.1186/s12874-021-01378-8] [Reference Citation Analysis]
96 George S, Bell EJ, Zheng Y, Kim R, White J, Devgan G, Smith J, Lal LS, Engel-Nitz NM, Liu FX. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors. Oncologist 2021;26:e1205-15. [PMID: 33955118 DOI: 10.1002/onco.13812] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Gamboa AC, Liu Y, Lee RM, Zaidi MY, Staley CA, Kooby DA, Winer JH, Shah MM, Russell MC, Cardona K, Maithel SK. Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel? J Surg Oncol 2019;120:1293-301. [PMID: 31621090 DOI: 10.1002/jso.25731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
98 Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 2016;79:70-5. [PMID: 27237061 DOI: 10.1016/j.jclinepi.2016.04.014] [Cited by in Crossref: 146] [Cited by in F6Publishing: 151] [Article Influence: 24.3] [Reference Citation Analysis]
99 Wu B, Cui Y, Tian J, Song X, Hu P, Wei S. Effect of second primary cancer on the prognosis of patients with non-small cell lung cancer. J Thorac Dis 2019;11:573-82. [PMID: 30963002 DOI: 10.21037/jtd.2018.11.96] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
100 Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW, Alizadeh AA, Diehn M. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017;7:1394-1403. [PMID: 28899864 DOI: 10.1158/2159-8290.cd-17-0716] [Cited by in Crossref: 273] [Cited by in F6Publishing: 147] [Article Influence: 54.6] [Reference Citation Analysis]
101 Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching PA, Solbach C, Schmutzler RK, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S; GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer 2022;160:100-11. [PMID: 34801353 DOI: 10.1016/j.ejca.2021.10.011] [Reference Citation Analysis]
102 Fallah J, Qunaj L, Olszewski AJ. Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database. Blood Adv 2016;1:112-21. [PMID: 29296804 DOI: 10.1182/bloodadvances.2016000927] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
103 Aspinall SL, Zhao X, Geraci MC, Good CB, Cunningham FE, Heron BB, Becker D, Lee S, Prasad V; Targeted Therapies in Veterans with RCC Study Group. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer Med 2019;8:6651-61. [PMID: 31536684 DOI: 10.1002/cam4.2531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
104 Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 2014;111:628-36. [PMID: 24921909 DOI: 10.1038/bjc.2014.307] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
105 Kappler P, Morgan MA, Ivanyi P, Brunotte SJ, Ganser A, Reuter CWM. Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients. Sci Rep 2021;11:16457. [PMID: 34385568 DOI: 10.1038/s41598-021-95874-y] [Reference Citation Analysis]
106 Jay M, Betensky RA. Displaying survival of patient groups defined by covariate paths: Extensions of the Kaplan-Meier estimator. Stat Med 2021;40:2024-36. [PMID: 33530128 DOI: 10.1002/sim.8888] [Reference Citation Analysis]
107 Zhong J, Switchenko J, Behera M, Kooby D, Maithel SK, McDonald MW, Lin JY, Cassidy RJ, El-Rayes B, Landry J, Patel PR. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Ann Surg Oncol 2018;25:1026-33. [PMID: 29327180 DOI: 10.1245/s10434-017-6322-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
108 Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, Polite BN, Chao Y, Walters I, Baudelet C, Lencioni R. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer 2014;3:439-50. [PMID: 26280005 DOI: 10.1159/000343872] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
109 Haug EB, Horn J, Markovitz AR, Fraser A, Klykken B, Dalen H, Vatten LJ, Romundstad PR, Rich-Edwards JW, Åsvold BO. Association of Conventional Cardiovascular Risk Factors With Cardiovascular Disease After Hypertensive Disorders of Pregnancy: Analysis of the Nord-Trøndelag Health Study. JAMA Cardiol 2019;4:628-35. [PMID: 31188397 DOI: 10.1001/jamacardio.2019.1746] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]